September 18, 2015

Allegra tablets had annual sales of approximately $60 million, based on IMS and IRI data for the 12 months ended June 2015.

September 18, 2015

The Centers for Disease Control and prevention this week announced that a new draft guideline for prescribing opioids to patients with chronic pain was in the works. 

September 11, 2015

Egalet Corporation on Thursday launched (oxycodone HCI) in the U.S.

September 10, 2015

However, patients in the 10-17 years age group also showed the greatest improvement in appropriate prescription drug use compared to all other age groups over a four-year period.

September 4, 2015

AstraZeneca on Thursday announced that the Food and Drug Administration approved Brilinta (ticagrelor) tablets at a 60 mg dose for patients with a history of heart attack beyond the first year.

August 19, 2015

A study conducted by researchers at Johns Hopkins Bloomberg School of Public Health has found that Florida’s legislative efforts to curb opioid abuse seem to be having their desired effect. 

August 17, 2015

The website includes sections about the importance of preventing abuse of prescription drugs and outlines the Food and Drug Administrations guidelines on abuse-deterrent labeling. 

August 10, 2015

According to the Substance Abuse Mental Health Services Administration, more than 24.5 million people age 12 or older in the U.S. (9.4% of the population) live with substance use disorders.

July 8, 2015

Finnish beauty brand Lumene is expanding its portfolio with the mid-August launch of its new Time Freeze Instant Lift V-Shaping Serum and Bright Now Vitamin C Shine Control Cream-Gel.

June 10, 2015

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.

May 4, 2015

Epic Pharma has added two new generic drugs to its portfolio of products.

March 31, 2015

The drug is Food and Drug Administration-approved to treat opioid-induced constipation in adults with chronic, non-cancer pain. 

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

February 27, 2015

Epic Pharma on Friday launched two generics: a schedule II pain reliever and a calcium channel blocker. 

February 25, 2015

In 10 years, the percentage of opioid analgesic users who used an opioid analgesic stronger than morphine increased from 17% to 37%, NCHS reported Wednesday. 

February 23, 2015

Vitamin supporting fertility health included in 52nd Annual Publicists Guild Awards swag bag last week. 

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 6, 2015

Prestige Brands will be resuming healthcare professional marketing programs in support of its Monistat vaginal treatments.

February 3, 2015

Iovate Health Sciences International on Monday introduced StrongGirl, a new line of supplements available exclusively at GNC and Lucky Vitamin Stores.

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

January 5, 2015

Healthy Mama on Monday launched Be Well Rounded!, a dye-free prenatal vitamin and DHA supplement system retailing at $29.99 for a two-month supply.

December 22, 2014

Mylan has announced the U.S. launch of its Estradiol Transdermal System USP, 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day (twice weekly), which is the generic version of Novartis' Vivelle-DOT.

December 22, 2014

Sandoz has announced the U.S. market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot, which is marketed by Novartis Pharmaceuticals.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.